Alnylam Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc.: Who Manages SG&A Costs Better?

Alnylam vs. Sarepta: SG&A Cost Management Showdown

__timestamp	Alnylam Pharmaceuticals, Inc.	Sarepta Therapeutics, Inc.
Wednesday, January 1, 2014	44526000	49315000
Thursday, January 1, 2015	60610000	75043000
Friday, January 1, 2016	89354000	83749000
Sunday, January 1, 2017	199365000	122682000
Monday, January 1, 2018	382359000	207761000
Tuesday, January 1, 2019	479005000	284812000
Wednesday, January 1, 2020	588420000	317875000
Friday, January 1, 2021	620639000	282660000
Saturday, January 1, 2022	770658000	451421000
Sunday, January 1, 2023	795646000	481871000
Monday, January 1, 2024	975526000

Igniting the spark of knowledge

Alnylam vs. Sarepta: A Decade of SG&A Management

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Over the past decade, Alnylam Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Alnylam's SG&A expenses surged by approximately 1,700%, reflecting its aggressive expansion strategy. In contrast, Sarepta's expenses grew by about 880%, indicating a more conservative approach.

Key Insights

2014-2016: Both companies maintained relatively low SG&A costs, with Alnylam slightly trailing behind Sarepta.
2017-2020: Alnylam's expenses began to outpace Sarepta's, peaking at nearly double by 2020.
2021-2023: Alnylam continued its upward trend, reaching a high of 795 million in 2023, while Sarepta's expenses rose to 482 million.

This analysis highlights the strategic differences in cost management between these two biotech giants.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025

Similar Statistics

Operational Costs Compared: SG&A Analysis of Novartis AG and Alnylam Pharmaceuticals, Inc.

Who Optimizes SG&A Costs Better? Zoetis Inc. or Sarepta Therapeutics, Inc.

Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights

Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.

Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared

Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated: SG&A Expense Trends

SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.

Breaking Down SG&A Expenses: Insmed Incorporated vs Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. vs Walgreens Boots Alliance, Inc.: SG&A Expense Trends

Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.

Sarepta Therapeutics, Inc. or MorphoSys AG: Who Manages SG&A Costs Better?

Who Optimizes SG&A Costs Better? Sarepta Therapeutics, Inc. or Evotec SE